| Source: |
Escherichia coli. |
| Molecular Weight: |
Approximately 9.1 kDa, a single non-glycosylated polypeptide chain containing 83 amino acids. |
| AA Sequence: |
MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSA |
| Purity: |
>98% by SDS-PAGE analyses.>90% by RP-HPLC analyses. |
| Biological Activity: |
Assay 1: Fully biologically active when compared to standard. Measured in a serum-free cell proliferation assay using human MCF-7 cells. The ED50 for this effect is 0.3-1.5 ng/mL, corresponding to a specific activity of > 6.7 × 105 U/mg.
Assay 2: Fully biologically active when compared to standard. The ED50 as determined by the stimulation of protein synthesis using rat L6 myoblasts is less than 10 ng/mL, corresponding to a specific activity of > 1.0 × 105 U/mg. |
| Physical Appearance: |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation: |
Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, pH7.2. |
| Endotoxin: |
Less than 0.01 EU/μg of rHuLR3 IGF-1 as determined by LAL method. |
| Reconstitution: |
Centrifuge the vial briefly before opening to ensure that the contents settle at the bottom. Reconstitute the vial with sterile distilled water or an aqueous buffer containing 0.1% BSA to achieve a concentration of 0.1-1.0 mg/mL. Divide the resulting stock solution into working aliquots and store them at or below -20°C. For further dilutions, use appropriate buffered solutions. |
| Stability & Storage: |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Refer to lot specific COA for the Use by Date when stored at 2 to 8°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution. |
| Synonyms: |
LR3 IGF-I |
| Background: |
Belonging to the insulin gene family, IGF-1 is a mitogenic polypeptide growth factor that stimulates the proliferation and survival of various cell types, including muscle, bone, and cartilage tissue in a laboratory setting. IGF-1 is mainly produced by the liver as an endocrine hormone and also in target tissues in a paracrine or autocrine manner. Its production is triggered by growth hormone (GH) and can be slowed by undernutrition, insensitivity to growth hormone, a lack of growth hormone receptors, or issues with the downstream signaling pathways post GH receptor, such as SHP2 and STAT5B. The LR3IGF-1 is a specialised version of human IGF-1, purposely designed and produced for mammalian cell culture to support the large-scale manufacturing of recombinant biopharmaceuticals. |
